Prostanoid function and cardiovascular disease

References

• Alfranca A, Iniguez M A, Fresno M, Redondo J M. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovasc Res 2006; 70(3)446–456
   PubMed Web of Science ®Google Scholar
• Babaev V R, Ding L, Reese J, Morrow J D, Breyer M D, Dey S K, Fazio S, Linton M F. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 2006; 113(1)108–117
   PubMed Web of Science ®Google Scholar
• Banfi C, Colli S, Eligini S, Mussoni L, Tremoli E. Oxidized LDLs influence thrombotic response and cyclooxygenase 2. Prostaglandins Leukot Essent Fatty Acids 2002; 67(2–3)169–173
   PubMed Web of Science ®Google Scholar
• Belton O, Fitzgerald D. Cyclooxygenase-2 inhibitors and atherosclerosis. J Am Coll Cardiol 2003; 41(10)1820–1822
   PubMed Web of Science ®Google Scholar
• Belton O, Fitzgerald D J. Cyclooxygenase isoforms and atherosclerosis. Expert Rev Mol Med 2003; 2003: 1–18
   Google Scholar
• Berger J, Moller D E. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–435
   PubMed Web of Science ®Google Scholar
• Blanco J C, Contursi C, Salkowski C A, DeWitt D L, Ozato K, Vogel S N. Interferon regulatory factor (IRF)- 1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 2000; 191(12)2131–2144
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M B, Hawkey C J, Hochberg M C, Kvien T K, Schnitzer T J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343(21)1520–1528, (2 pages following 1528)
   PubMed Web of Science ®Google Scholar
• Bunting S, Moncada S, Vane J R. The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983; 39(3)271–276
   PubMed Web of Science ®Google Scholar
• Burleigh M E, Babaev V R, Oates J A, Harris R C, Gautam S, Riendeau D, Marnett L J, Morrow J D, Fazio S, Linton M F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105(15)1816–1823
   PubMed Web of Science ®Google Scholar
• Burleigh M E, Babaev V R, Yancey P G, Major A S, McCaleb J L, Oates J A, Morrow J D, Fazio S, Linton M F. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005; 39(3)443–452
   PubMed Web of Science ®Google Scholar
• Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99(3)132–140
   PubMed Web of Science ®Google Scholar
• Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, De Luca M, Prontera C, Chiarelli F, Cuccurullo F, Mezzetti A. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler Thromb Vasc Biol 2004; 24(7)1259–1265
   PubMed Web of Science ®Google Scholar
• Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104(8)921–927
   PubMed Web of Science ®Google Scholar
• Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 2007; 78(2)96–110
   PubMedGoogle Scholar
• Chandrasekharan N V, Dai H, Roos K L, Evanson N K, Tomsik J, Elton T S, Simmons D L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99(21)13926–13931
   PubMed Web of Science ®Google Scholar
• Cheng Y, Austin S C, Rocca B, Koller B H, Coffman T M, Grosser T, Lawson J A, FitzGerald G A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296(5567)539–541
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, Lawson J, Funk C D, Fitzgerald G A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006; 116(5)1391–1399
   PubMed Web of Science ®Google Scholar
• Dannhardt G, Kiefer W. Cyclooxygenase inhibitors – current status and future prospects. Eur J Med Chem 2001; 36(2)109–126
   PubMed Web of Science ®Google Scholar
• Davidge S T. Prostaglandin H synthase and vascular function. Circ Res 2001; 89(8)650–660
   PubMed Web of Science ®Google Scholar
• Diaz-Cazorla M, Perez-Sala D, Ros J, Jimenez W, Fresno M, Lamas S. Regulation of cyclooxygenase-2 expression in human mesangial cells – transcriptional inhibition by IL-13. Eur J Biochem 1999; 260(1)268–274
   PubMedGoogle Scholar
• Egan K M, Lawson J A, Fries S, Koller B, Rader D J, Smyth E M, Fitzgerald G A. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306(5703)1954–1957
   PubMed Web of Science ®Google Scholar
• FitzGerald G A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2(11)879–890
   PubMed Web of Science ®Google Scholar
• FitzGerald G A, Austin S, Egan K, Cheng Y, Pratico D. Cyclo-oxygenase products and atherothrombosis. Ann Med 2000; 32(Suppl 1)21–26
   PubMedGoogle Scholar
• FitzGerald G A, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345(6)433–442
   PubMed Web of Science ®Google Scholar
• Flavahan N A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 2007; 28(3)106–110
   PubMed Web of Science ®Google Scholar
• Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 2005; 35(4)347–385
   PubMed Web of Science ®Google Scholar
• Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim H S, Rockman H A, FitzGerald G A, Koller B H, Coffman T M. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2005; 2(3)201–207
   PubMed Web of Science ®Google Scholar
• Fuse I, Higuchi W, Aizawa Y. Pathogenesis of a bleeding disorder characterized by platelet unresponsiveness to thromboxane A2. Semin Thromb Hemost 2000; 26(1)43–45
   PubMed Web of Science ®Google Scholar
• Grau R, Iniguez M A, Fresno M. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res 2004; 64(15)5162–5171
   PubMed Web of Science ®Google Scholar
• Hansson G K, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6(7)508–519
   PubMed Web of Science ®Google Scholar
• Hata A N, Breyer R M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103(2)147–166
   PubMed Web of Science ®Google Scholar
• Helliwell R J, Adams L F, Mitchell M D. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004; 70(2)101–113
   PubMed Web of Science ®Google Scholar
• Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94(4)1662–1667
   PubMed Web of Science ®Google Scholar
• Ide T, Egan K, Bell-Parikh L C, FitzGerald G A. Activation of nuclear receptors by prostaglandins. Thromb Res 2003; 110(5–6)311–315
   PubMed Web of Science ®Google Scholar
• Iniguez M A, Martinez-Martinez S, Punzon C, Redondo J M, Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000; 275(31)23627–23635
   PubMed Web of Science ®Google Scholar
• Iniguez M A, Punzon C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999; 163(1)111–119
   PubMed Web of Science ®Google Scholar
• Iniguez M A, Rodriguez A, Volpert O V, Fresno M, Redondo J M. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9(2)73–78
   PubMed Web of Science ®Google Scholar
• Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003; 69(2–3)187–194
   PubMed Web of Science ®Google Scholar
• Kanaoka Y, Urade Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 2003; 69(2–3)163–167
   PubMed Web of Science ®Google Scholar
• Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271(20)12042–12048
   PubMed Web of Science ®Google Scholar
• Kearney P M, Baigent C, Godwin J, Halls H, Emberson J R, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553)1302–1308
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita J K, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114(6)784–794
   PubMed Web of Science ®Google Scholar
• Kujubu D A, Herschman H R. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992; 267(12)7991–7994
   PubMed Web of Science ®Google Scholar
• Lopez J A, Armstrong M L, Harrison D G, Piegors D J, Heistad D D. Vascular responses to leukocyte products in atherosclerotic primates. Circ Res 1989; 65(4)1078–1086
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007; 13(22)2215–2227
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Jama 2006; 296(13)1633–1644
   PubMed Web of Science ®Google Scholar
• Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68–69: 165–175
   PubMed Web of Science ®Google Scholar
• Murakami M, Kambe T, Shimbara S, Kudo I. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J Biol Chem 1999; 274(5)3103–3115
   PubMed Web of Science ®Google Scholar
• Murakami M, Nakashima K, Kamei D, Masuda S, Ishikawa Y, Ishii T, Ohmiya Y, Watanabe K, Kudo I. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 2003; 278(39)37937–37947
   PubMed Web of Science ®Google Scholar
• Murakami M, Nakatani Y, Tanioka T, Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002; 68/69: 383–399
   Web of Science ®Google Scholar
• Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388(6643)678–682
   PubMed Web of Science ®Google Scholar
• Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 1997; 89(5)1621–1628
   PubMed Web of Science ®Google Scholar
• Norata G D, Callegari E, Inoue H, Catapano A L. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004; 24(5)871–877
   PubMed Web of Science ®Google Scholar
• Pratico D, Tillmann C, Zhang Z B, Li H, FitzGerald G A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 2001; 98(6)3358–3363
   PubMed Web of Science ®Google Scholar
• Ray W A, Stein C M, Daugherty J R, Hall K, Arbogast P G, Griffin M R. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339)1071–1073
   PubMed Web of Science ®Google Scholar
• Reiss A B, Edelman S D. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol 2006; 4(4)395–408
   PubMedGoogle Scholar
• Rocca B, Loeb A L, Strauss J F, 3rd, Vezza R, Habib A, Li H, FitzGerald G A. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 2000; 6(2)219–221
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340(2)115–126
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dube C, Jolicoeur E, Boucher M, Joyce J, Tugwell P, Wells G W. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5(7)818–828, 828 e1–5; quiz 768
   PubMed Web of Science ®Google Scholar
• Rudic R D, Brinster D, Cheng Y, Fries S, Song W L, Austin S, Coffman T M, FitzGerald G A. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005; 96(12)1240–1247
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Morgenstern R, Jakobsson P J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007; 59(3)207–224
   PubMed Web of Science ®Google Scholar
• Scher J U, Pillinger M H. 15d-PGJ2: the anti-inflammatory prostaglandin. Clin Immunol 2005; 114(2)100–109
   PubMed Web of Science ®Google Scholar
• Simmons D L, Botting R M, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56(3)387–437
   PubMed Web of Science ®Google Scholar
• Smith W L, DeWitt D L, Garavito R M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145–182
   PubMed Web of Science ®Google Scholar
• Smyth E M, FitzGerald G A. Human prostacyclin receptor. Vitam Horm 2002; 65: 149–165
   PubMed Web of Science ®Google Scholar
• Straus D S, Glass C K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21(3)185–210
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Dannenberg A J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24(2)96–102
   PubMed Web of Science ®Google Scholar
• Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68/69: 95–114
   Web of Science ®Google Scholar
• Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000; 275(42)32775–32782
   PubMed Web of Science ®Google Scholar
• Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J 2001; 15(12)2057–2072
   PubMed Web of Science ®Google Scholar
• Thomas D W, Mannon R B, Mannon P J, Latour A, Oliver J A, Hoffman M, Smithies O, Koller B H, Coffman T M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998; 102(11)1994–2001
   PubMed Web of Science ®Google Scholar
• Topper J N, Cai J, Falb D, Gimbrone M A, Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93(19)10417–10422
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins. Other Lipid Mediat 2002; 68/69: 535–556
   Web of Science ®Google Scholar
• Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 2005; 338(1)70–76
   PubMed Web of Science ®Google Scholar
• Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482(1–2)259–271
   PubMed Web of Science ®Google Scholar
• Vane J R. Biomedicine. Back to an aspirin a day? Science 2002; 296(5567)474–475
   Google Scholar
• Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis. Med Res Rev 2004; 24(4)399–424
   PubMed Web of Science ®Google Scholar
• Wang L H, Kulmacz R J. Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat 2002; 68/69: 409–422
   Web of Science ®Google Scholar
• Wang M, Zukas A M, Hui Y, Ricciotti E, Pure E, FitzGerald G A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 2006; 103(39)14507–14512
   PubMed Web of Science ®Google Scholar
• Warner T D, Giuliano F, Vojnovic I, Bukasa A, Mitchell J A, Vane J R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96(13)7563–7568
   PubMed Web of Science ®Google Scholar
• Warner T D, Mitchell J A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 2004; 18(7)790–804
   PubMed Web of Science ®Google Scholar
• Watanabe K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 2002; 68/69: 401–407
   Web of Science ®Google Scholar
• Williams C S, Mann M, DuBois R N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18(55)7908–7916
   PubMed Web of Science ®Google Scholar
• Wu K K, Liou J Y. Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun. 2005
   Google Scholar
• Yamada M, Numaguchi Y, Okumura K, Harada M, Naruse K, Matsui H, Ito T, Hayakawa T. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thromb Vasc Biol 2002; 22(2)256–262
   PubMed Web of Science ®Google Scholar
• Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, Kinoshita T, Okabe M, Tanabe T. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002; 106(18)2397–2403
   PubMed Web of Science ®Google Scholar
• Yu Y, Cheng Y, Fan J, Chen X S, Klein-Szanto A, Fitzgerald G A, Funk C D. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 2005; 115(4)986–995
   PubMed Web of Science ®Google Scholar